This preliminary hinted that immune status between STS patients in high and low FAS groups might be relevant to clinical outcomes, although the detailed association between TMB and prognosis remains controversial and varies across cancer types (Wang et al., 2021; Qing et al., 2022). This evidence concerns the gene FAS and cancer.